SPARC Q1 FY27 results: loss narrows, revenue rises sharply

Pat NegativeRevenue Growth 20pctRelated Party TransactionsExceptional ItemResults View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹212.40

prior close

₹212.60

announcement price

In-mkt

timing

Nifty Microcap 250market-0.1%-2.3% vs market

Pharmaceuticals peers, median of 165sector-0.1%-2.3% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.5

10m

+0.8

15m

+1.1

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4-0.1-2.3-0.1-2.3

Next day

-3.3-0.2-3.1+0.0-3.4

-4.9+0.1-5.0-0.0-4.8

-3.5+0.3-3.8+0.3-3.8

-6.3+0.4-6.7-0.5-5.8

-6.7+0.5-7.2-1.1-5.5

-9.2+0.3-9.5-1.8-7.3

15d

-6.5+1.9-8.4+0.2-6.7

-7.3+2.2-9.5+1.7-9.0

-13.3-1.2-12.1-1.8-11.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SPARC Board approved Q1 FY27 results. Revenue from operations rose to Rs 3,992 lakhs from Rs 964 lakhs year-on-year, aided by Rs 2,921 lakhs from terminating its CMS licensing deal. Standalone loss narrowed to Rs 2,098 lakhs from Rs 5,203 lakhs. Loss per share improved to Rs 0.65 from Rs 1.60. Board also cleared reclassification of certain promoter group individuals to public category.

Likely market impact

Quarterly losses persist though improving. Promoter group reclassification may reduce promoter shareholding.